Company news
Clarity Pharmaceuticals Ltd. news in 2025
Clarity Pharmaceuticals Ltd.'s news releases, calls and decks from 2025, newest first.
Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026
December 24, 2025
Co-PSMA abstract accepted for oral presentation at EAU
December 23, 2025
Positive guidance from the US FDA on Cu-64 SARTATE Phase III
December 21, 2025
AGM MD Presentation
November 24, 2025
Clarity signs copper-67 Supply Agreement with Nusano
October 16, 2025
Co-PSMA trial achieves primary endpoint
October 14, 2025
S&P DJI Announces September 2025 Quarterly Rebalance
September 5, 2025
Preliminary Final Report
August 28, 2025
Clarity successfully completes $203 million institutional pl
July 28, 2025
Co-PSMA trial: Recruitment successfully completed
July 17, 2025
Co-PSMA trial recruitment successfully completed
July 17, 2025
Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx
June 17, 2025
Clarity enters a Commercial Manufacturing Agreement
June 16, 2025
SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging
June 13, 2025
SABRE topline results
June 13, 2025
DISCO topline results: 64Cu-SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway.
June 5, 2025
DISCO topline results
June 5, 2025
First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CT
May 29, 2025
First patient imaged in Phase III AMPLIFY trial
May 28, 2025
Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences
May 20, 2025
AMPLIFY trial commences
May 20, 2025
Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano
April 17, 2025
Clarity signs commercial-scale copper-64 Supply Agreement
April 17, 2025
$11.1 million RDTI and refocus on high-priority programs
April 17, 2025
SECuRE trial update: First patient treated in the Phase II Cohort Expansion
April 15, 2025
First patient treated in the Phase II of the SECuRE trial
April 15, 2025
SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.
March 5, 2025
Clarity signs Cu-64 Supply Agreement with UQ
March 4, 2025
Appendix 4D
February 28, 2025
Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA
February 19, 2025
Clarity receives US FDA FTD for the treatment of mCRPC
February 18, 2025
Clarity expands pipeline with Cu-64/67 SAR-trastuzumab
February 10, 2025
Clarity to present COBRA and CLARIFY abstracts
January 27, 2025
Clarity receives U.S. FDA Fast Track Designation
January 23, 2025
Decks in 2025
- Shareholder Meeting (November 2025)
Shareholder meeting · 24 slides · Nov 25, 2025
- Canaccord Drug and Device Conference 2025
Conference · 12 slides · October 2025